For patients with cancer, primary care professionals help promote cancer prevention, early detection, and survivorship care. However, gaps in coordination and collaboration between primary care and oncology may significantly impact long-term survival outcomes.
Next-gen BCL-2 inhibitors show promise in RRMM as venetoclax struggles with OS in phase 3 BELLINI study.
Guest contributor Moaath Mustafa Ali, MD, MPH, outlines the transforming treatment paradigm of Ph+ ALL.
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Podcasts
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Dr. Amir Fathi discusses oral regimens and future AML therapy trends in this Editor’s Special of The HemOnc Pulse.
Can tech bridge the cancer care gap? Dr. Banerjee and Dr. Longmire explore solutions for drug accessibility.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
At The HemOnc Pulse Live!, experts debate key controversies in MDS care, from frontline therapy to emerging treatments.
Gurbakhash Kaur, MD joins the host of The HemOnc Pulse Live! for a comprehensive discussion about the RedirecT-1 trial.
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
Study finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
Yesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology